Standardizing the pH of the sample can minimize intersample variation in the chemical shift of resonances (1, 2) and helped us in interpreting the plasma spectra. This step is even more beneficial for urine and CSF spectra because pH of these body fluids has a greater intersample variation (1, 2) . Minimizing intersample variation of the chemical shift of a resonance will be of great help for future automation of spectral analysis (assignment and quantification of metabolites). We agree with Des et al. that there seems to be no ideal pH that can avoid overlap of resonances.
In our choice of pH we were lead by the arguments given in the earlier study by Lehnert and Hunkler (4) and by their already available database of relevant metabolites at this pH. iles et al. suggest measuring the sample first at its natural pH, followed by repeat analyses at acidic (2.5) and alkaline pH (8.5) if necessary.
Analytically,
there are no reasons to prefer the physiological pH of the sample. Given the complexity of the spectra and the intersample variability in pH, it is not enough to record the pH of the sample. The natural pH of the sample simply has an unacceptable intersample variation (especially urine and CSF), which hampers the assignment of resonances. This may be why Des et al. require the presence of both the doublet and the quartet resonances from methylmalomc acid for the diagnosis of methylmalonic aciduria from a urine sample. To be able to use the same model compound database for the interpretation of spectra from all body fluids, we decided to use a common pH (2.50) throughout our work (blood plasma, CSF, and urine). This seems more straightforward than working at three different pH values to avoid a simple two-step sample preparation (1. remove proteins by filtration, 2. control pH) before evaporation and reuptake in DO. We do not consider this "a complex sample preparation" that uses "a lengthy extraction procedure" (1, 2) .
The spectrometer. To evaluate the patient's responsiveness to vitamin B6, we gave him a trial of 300-mg tablets of vitamin B6 three times daily for -40 days. At the end of this trial, his fresh urine was tested with a sulfite test strip (Merckoquant 10013), in an attempt to appreciate a possible enhancement of his deficient enzymatic activity (cystathionine 13-synthase) with secondary excretion of sulfite. This teststrip reaction was positive, although both parents and one brother gave negative reactions. His plasma methionine content was still high (433 mo1JL), and the patient was considered vitamin B6-unresponsive. Samples of plasma, urine, and skin biopsy were sent to Jean-Marie Saudubray (Necker Hospital, Paris, France) for confirmation of the diagnosis of homocystinuria. A later check of the patient's urine while he was on a lowprotein diet containing betaine citrate at 6 g daily gave a negative result for the suffite test.
To identify the compound responsible for the positive sulfite test in this patient's earlier urine, we investigated several prepared solutions. Only compounds with free-SH radicals, such as homocysteine, gave positive reactions ( Table 1 ). In particular homocysteine gave a positive result at a concentration of 0.5 mmolIL; in comparison, a fivefold higher concentration of sodium suffite was required. Despite the sensitivity of this reaction, both parents, who are obligate heterozygotes for homocystinuria, gave negative sulfite tests.
Because molybdenum cofactor deficiency and homocystinuria share similar clinical presentations, mainly dislocated ocular lenses, methods more specific for each disorder should be used for their differentiation. As indicated in Table 1 , all CA 19-9 concentrations estimated by the IMx kit were high, ranging from 165 to 3881 kJUIL (upper limit of normal = 37 kIU/ L). The calibration curve ranges from 0 to 500 kJU/L, and serum samples yielding >500 kItJ/L were diluted in the dilution buffer provided by the manufacturer. The investigations undertaken failed to find the usual causes. Thus, no pancreatic, liver, or gastrointestinal tract tumors could be detected by transabdominal and endoscopic ultrasonography, computed tomography, and endoscopic examination. Furthermore, neither cholelithiasis nor cholangitis was present. It is unlikely that the benign tumor of the spinal cord is responsible for this large increase in the CA 19.9 concentrations, as no such case has been reported to date. As seen in Table 1 (4, 5) , though the latter was not reported on the Abbott CA 19.9 assay information leaflet. When we tested whether human anti-murine antibodies (HAMA) and rheumatoid factors were responsible for these results, the screening for HAMA was negative; the screening for rheumatoid factors in serum sample no. 7 was positive (1gM class) by an in-house enzyme immunoassay.
We concluded, therefore, that rheumatoid factors probably interfere with the AbbOtt IMx kit and could be responsible for the high results obtained. Nevertheless, this interference should be confirmed by further studies of serum samples with known rheumatoid factors. Thus, possible interference of
